The M2Gen Board oversees the collaboration between Moffitt and Merck & Co., Inc., that seeks to expand Moffitt’s efforts in research and biotechnology while developing and commercializing the means to prescribe and deliver personalized cancer care. This innovative collaboration is developing one of the largest tissue bio-repositories and relational databases in the country, with the goal of combining molecular profiling technology with clinical response to improve cancer prevention, diagnosis and treatment.
| 
Theodore J. Couch, Sr., Chair | | 
William S. Dalton, Ph.D., M.D.
CEO, M2Gen
Director, Personalized Medicine Institute, Moffitt Cancer Center |
| | |
| 
Kenneth Ford, Ph.D.
Founder and CEO
Florida Institute for Human & Machine Cognition | | 
Jack A. Kolosky
Executive Vice President
Chief Operating Officer
President, Moffitt Hospital |
| 
Senator Connie Mack
Liberty Partners Group | | 
Kenneth I. Moch
President/CEO,
Chimerix |
| 
The Honorable H. Lee Moffitt
Former Speaker, Florida House of Representatives;
Founder, H. Lee Moffitt Cancer Center & Research Institute | | 
Linda Powers
Tucan Capital Fund
|
| 
Robert Rothman
CEO/President,
Black Diamond Group
| | 
Daniel Sullivan, M.D.
Associate Center Director for Clinical Investigations,
H. Lee Moffitt Cancer Center & Research Institute; Chief Medical Officer, M2Gen
|